Arndt Vogel

Arndt Vogel, MD is a Professor of Gastroenterology and Hepatology who has worked at Hannover Medical School (Germany) and, most recently, at the University of Toronto/University Health Network, where he continues to lead an internationally recognized program in hepatobiliary oncology. He is one of Europe's foremost experts on cholangiocarcinoma, with a particular focus on FGFR2 fusion-positive intrahepatic cholangiocarcinoma (iCCA)—a molecular subtype representing approximately 10–15% of iCCA cases that is highly actionable with selective FGFR2 inhibitors. Dr. Vogel served as a key investigator and European leader for the FIGHT-202 trial (pemigatinib) and the PROOF trial (infigratinib), studies that established the first targeted therapies approved specifically for FGFR2-fusion cholangiocarcinoma. Beyond FGFR2, he has contributed to the clinical development of IDH1 inhibitors, HER2-targeted therapies, and immunotherapy combinations in BTC. His translational research program interrogates mechanisms of resistance to FGFR inhibitors, including FGFR2 kinase domain mutations and adaptive FGF ligand upregulation, and explores strategies to overcome or prevent such resistance.